AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 32 min read$STTK

Shukla Abhinav A. sold $166K of STTK

Shukla Abhinav A. (Chief Technical Officer) sold 23,465 shares of Shattuck Labs, Inc. (STTK) at an average of $7.08 ($7.07–$7.08, $0.17M total) across 2 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shukla Abhinav A.
Published Jul 3, 2026, 12:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$STTK
Neutral
high confidence
Mentioned
$STTK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STTKNeutralLow
01

Why it matters

A CTO open-market sale of ~$166k occurred across two trades, explicitly under a pre-arranged 10b5-1 plan, with no other company-specific news included.

02

Market read

Traders may monitor for sentiment impact, but the 10b5-1 framing reduces the likelihood of a fundamental read-through.

03

What to watch

The article provides sale size and price range but no context on total insider holdings, tax planning, or whether other insiders also sold/bought around the same period.

Relevance 3/10Novelty 3/10Timing: Immediately after the Form 4 filing (filed 2026-07-02) for near-term sentiment checks.

Background

The article is a SEC Form 4 insider transaction disclosure for Shattuck Labs, Inc. (STTK).

Company-level read

Ticker impact

$STTKNeutralHigh confidence
Context

Shattuck Labs insider (CTO) filed a Form 4 open-market sale of 23,465 shares at ~$7.08 during 2026-06-30 to 2026-07-01.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 sale (not a buy), explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change.

Market effects

Sector

Minimal; single-company insider transaction without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales under 10b5-1 can be purely liquidity-driven, so the signal may be closer to neutral than negative.

Key entities

  • company
    Shattuck Labs, Inc.

    Issuer of the Form 4 insider transaction; subject of the filing.

  • insider
    Shukla Abhinav A.

    Chief Technical Officer who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 25
$STTKMed

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.

fool.com3 min
JUN 10
$STTKMedAI 8/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.

rttnews.com2 min
JUN 10
$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 shares at $4.00 each and pre-funded warrants for up to 7,870,624 shares at $3.9999 each, with a $0.0001 exercise price. Gross proceeds are expected at about $75 million before underwriting costs. The deal is set to close June 11, 2026, with a 30-day option for 2,812,500 additional shares.

manilatimes.net4 min
JUN 10
$STTKMedAI 9/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant, according to the company. Gross proceeds are expected at about $75 million before fees. The deal is set to close June 11, with a 30-day option for up to 2.81 million additional shares.

rttnews.com2 min
JUN 9
$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs (NASDAQ: STTK) said it has commenced a proposed public offering of its common stock, or pre-funded warrants in lieu of stock for certain investors. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of shares at the offering price. Terms and size are subject to market conditions.

manilatimes.net3 min
JUN 5
$STTKMedAI 9/10

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs (NASDAQ: STTK) said it will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics and immunogenicity, plus a pipeline update. Management including CEO Taylor Schreiber and CFO Andrew Neill will present, followed by Q&A.

manilatimes.net2 min